Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TTCC-2022-02: A Phase II, Multicenter, Randomized Study of Cetuximab Plus/ Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)

NCT06856213 is registered in ClinicalTrials.gov with Grupo Español de Tratamiento de Tumores de Cabeza y Cuello as lead sponsor.

NCT NCT06856213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06856213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TTCC-2022-02: A Phase II, Multicenter, Randomized Study of Cetuximab Plus/ Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase
Phase 2
Overall status
Recruiting
Start date
June 18, 2025
Completion date
October 31, 2028
Enrollment
65 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent / metastatic head and neck squamous cell carcinoma